Novartis (NOVN) Status Update summary

Strategic focus and business transformation

• Transitioned to a pure-play innovative medicines company, focusing on four core therapeutic areas and five advanced technology platforms for future growth.

• Prioritizes operational excellence, data science, and agile resource allocation to drive sustainable growth and R&D productivity.

• Social impact and sustainability efforts are structured around global health innovation, inclusion and access, environmental sustainability, ethics, and people experience.

Global health innovation and pipeline

• Advanced a robust Global Health pipeline, with 11 clinical trials across 14 low and middle-income countries, targeting neglected diseases like malaria, sickle cell, leishmaniasis, dengue, and Chagas disease.

• Malaria pipeline includes new therapies such as ganaplacide/lumefantrine and KLU156, both showing high efficacy and addressing drug resistance.

• Launched Coartem Baby, the first antimalarial for newborns, through global partnerships, filling a critical treatment gap.

• Maintains a 25-year commitment to malaria, surpassing 1 billion treatments delivered and continuing innovation for future needs.

• Ongoing commitment to neglected tropical diseases, with significant R&D investment and partnerships to address unmet needs in low- and middle-income countries.

Inclusion, access, and health equity

• Access Principles are embedded across the product lifecycle, focusing on affordability, health systems strengthening, and adaptive development.

• Inclusive Health Accelerators (IHAs) use data-driven approaches to identify underserved populations and implement targeted interventions, such as community education, patient navigation, provider training, and impact measurement.

• IHAs are launching in the US with a focus on prostate cancer, cardiovascular disease, and breast cancer, and plan to expand to other geographies.

• Initiatives aim to build trust, improve diagnosis and treatment, and create sustainable business growth while expanding access.